On January 5, 2021 Revitope Oncology Inc. (Revitope), a biotechnology company advancing a new class of precision cancer immunotherapies, reported that the company has entered into a collaboration with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, evaluating Revitope’s proprietary T cell engager technology platform to develop next generation bi-specific antibody therapies (Press release, Revitope Oncology, JAN 5, 2021, View Source [SID1234633660]). The agreement was facilitated by Johnson & Johnson Innovation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to enter into this collaboration with Janssen and employ Revitope’s PrecisionGATE technology platform to advance the development of T cell engager therapies with the aim of delivering safer, more efficacious therapies to patients," said Steve Arkinstall, Ph.D., Chief Executive Officer, Revitope Oncology. "This marks our second collaboration in the last 6 months as we continue to accelerate the potential of our platform and generate more effective targeted cancer therapeutics."
Revitope’s proprietary Precision Guided Antibody Tumor Engager (PrecisionGATE) technology platform exploits co-expressed tumor antigens to enable the development of highly specific cancer drugs with improved safety and efficacy over conventional immunotherapeutic approaches. The company’s unique approach combines a pair of tumor-targeted antibodies with a shared silent T cell engaging domain that become active only when they encounter cancer cells co-expressing both antigens. This allows for highly selective dual-antigen targeting to elicit and focus a powerful gated immune response to tumor cells.
Under the terms of the collaboration, Revitope will collaborate with Janssen to conduct a feasibility study in the evaluation of Revitope’s PrecisionGATE T cell engager platform.